Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

Kiniksa Pharmaceuticals International (KNSA) EBITDA Margin (2021 - 2026)

Kiniksa Pharmaceuticals International filings provide 6 years of EBITDA Margin readings, the most recent being 10.25% for Q1 2026.

  • On a quarterly basis, EBITDA Margin rose 405.0% to 10.25% in Q1 2026 year-over-year; TTM through Mar 2026 was 9.62%, a 1317.0% increase, with the full-year FY2025 number at 8.73%, up 1897.0% from a year prior.
  • EBITDA Margin hit 10.25% in Q1 2026 for Kiniksa Pharmaceuticals International, up from 7.09% in the prior quarter.
  • In the past five years, EBITDA Margin ranged from a high of 226.07% in Q3 2022 to a low of 78.43% in Q1 2022.
  • Median EBITDA Margin over the past 5 years was 3.09% (2022), compared with a mean of 4.49%.
  • Biggest five-year swings in EBITDA Margin: skyrocketed 47920bps in 2022 and later plummeted -24675bps in 2023.
  • Kiniksa Pharmaceuticals International's EBITDA Margin stood at 3.09% in 2022, then surged by 1081bps to 30.27% in 2023, then plummeted by -124bps to 7.35% in 2024, then skyrocketed by 196bps to 7.09% in 2025, then skyrocketed by 45bps to 10.25% in 2026.
  • The last three reported values for EBITDA Margin were 10.25% (Q1 2026), 7.09% (Q4 2025), and 10.14% (Q3 2025) per Business Quant data.